CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic colorectal cancer
Epistemonikos ID: e7d5e8c97259c50cdfa7af1df37879e42e99fe34
First added on: Sep 03, 2026